Identical ph III trials reveal different results

By Melissa Fassbender

- Last updated on GMT

The studies included more than 2,100 people across 28 countries. (Image: iStock)
The studies included more than 2,100 people across 28 countries. (Image: iStock)

Related tags Monoclonal antibodies Clinical trial

Genentech, a member of the Roche Group, has announced top-line results from two phase III studies, which had conflicting results.

The LAVOLTA I-II studies were identical, double-blind, randomized, multi-center, placebo-controlled studies designed to evaluate the efficacy and safety of lebrikizumab – a novel humanized monoclonal antibody designed to treat severe asthma.

Together, the studies included more than 2,100 people across 28 countries.

According to the company’s recent release, one study met its primary endpoint (showing lebrikizumab significantly reduced exacerbations in people with severe asthma); however, the second study did not meet statistical significance.

It is too early to determine why the results of the LAVOLTA I study and LAVOLTA II study are different​,” a Roche spokesperson told Outsourcing-Pharma.com.
The conflicting results highlight the difficulties faced in clinical trials. As such, the company plans on submitting the results for presentation at forthcoming medical meetings after analyzing the data to better understand the results.

We were hopeful these identical studies would confirm the phase II results because there is still a significant unmet need for people with severe asthma​,” said Sandra Horning, M.D., Chief Medical Officer and Head of Global Product Development at Roche.

These data require further interpretation and analyses are ongoing to better understand the results and determine next steps​.”

Related topics Clinical Development Phase III-IV

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers